- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Immune Antibody Preparation Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates
- Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
- A Brief Discussion on Prokaryotic Expression of Recombinant Antibodies
- Common Problems and Solutions for Recombinant Antibody Yeast Expression Experiments
- Common Problems and Solutions for Recombinant Antibody Expression Experiments in lactation
Special topic on antibody modification
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
- Overview of Yeast Two Hybrid Technology
- Yeast Display Platform for Rapid Nanobody Discovery
- What is the essential difference between antibody phage display and yeast display?
- Yeast One Hybrid FAQ
Yeast Display Technology Special Topic
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
- Antibody Affinity Test EC50
- Antibody Full Length Sequencing
Antibody Detection Service Topic
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
- Non-Invasive In Vivo Monitoring of PROTAC-Mediated Protein Degradation Using an Environment-Sensitive Reporter
- How do you know Phage Display Peptide Library?
- Phage Display Peptide Library
- Phage Display Antibody Library Technology
- Efficient Screening Methods and Research Progress of Anti-tumor Polypeptides
- Molecular Screening and Application of Targeted Peptides
- Screening Strategies for Cyclic Peptide Drugs
- Construction Method of Random Peptide Library
- Construction and Screening of Peptide Library
Special Topic on Phage Display Technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
TekBiotech has 10 years of project development experience and insights in drug antibody discovery and is able to provide customers with high-quality nanoantibody yeast display services.
Based on phage display technology, TekBiotech focuses on providing one-stop scientific research services, including phage antibody library construction and screening, antibody humanization, human Fab antibody library construction, human scFV antibody library construction, phosphorylated antibody customization and other technical services, and can customize suitable experimental plans for customers.
TekBiotech has mature antibody humanization technology, which can humanize antibody sequences and ensure that the affinity of the modified humanized antibodies remains at the same order of magnitude. We provide guaranteed humanization services to facilitate your experiments.
TekBiotech has extensive experience in antibody engineering construction. Based on the antibody phage display library platform, we are able to provide chimeric antibody modification services with high affinity and low immunogenicity.
TekBiotech's own mammalian expression system high-yield series vectors and domesticated 293 series and CHO series cells can achieve efficient secretory expression of full-length antibodies and various forms of recombinant antibody fragments.
Tek Biotech is committed to building a complete one-stop technical service platform that can provide a series of services from bioinformatics analysis, humanized antibody design, antibody expression and purification, to affinity determination, antibody affinity maturation, etc. to meet the needs of different customers.
TekBiotech has a complete recombinant antibody expression production platform, rich experience in recombinant protein and recombinant antibody expression, and based on phage display technology, we can provide customers with high-quality recombinant antibody preparation and screening services.
TekBiotech has complete upstream and downstream docking services for nano-antibody preparation, including expression and purification of antigens and antibodies, antibody humanization, recombinant antibody expression and other services.
TekBiotech has mature animal immunization technology and PBMC separation technology to ensure that cells are not damaged or stimulated during the separation process. The subsequent purification technology ensures the purity and viability of camel mononuclear cells and other technical indicators, which is suitable for subsequent cell culture, antibody preparation and other research.
Tekbiotech has been committed to the field of nanoantibodies for many years and has provided high-quality products and services to many customers. Tekbiotech has rich experience in antibody engineering construction and is able to provide three-dimensional upstream and downstream antibody services to meet the scientific research requirements of different customers.
